Nektar Therapeutics (NKTR) Profit After Tax (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Profit After Tax of -$44.9 million for Q1 2026, up 11.75% year-over-year from -$40.2 million in Q1 2025, and down 24.46% quarter-over-quarter from -$36.1 million in Q4 2025.
Nektar Therapeutics (NKTR) Profit After Tax (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at -$44.9 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 11.75% year-over-year to -$44.9 million; the TTM figure through Mar 2026 stood at -$158.2 million (down 18.79% YoY), while the FY2025 annual figure was -$164.1 million, down 37.92% from the prior year.
- Profit After Tax for Q1 2026 stood at -$44.9 million, down from -$36.1 million in the prior quarter.
- The five-year high for Profit After Tax was $7.3 million in Q4 2024, with the low at -$160.7 million in Q2 2022.
- The 5-year median for Profit After Tax is -$45.8 million (2023), against an average of -$57.4 million.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax jumped 117.26% in 2024, then tumbled 596.89% in 2025.
- Nektar Therapeutics' Profit After Tax stood at -$59.7 million in 2022, then advanced by 29.5% to -$42.1 million in 2023, then soared by 117.26% to $7.3 million in 2024, then sank by 596.89% to -$36.1 million in 2025, then fell by 24.46% to -$44.9 million in 2026.
- Business Quant data shows NKTR's Profit After Tax at -$44.9 million in Q1 2026, -$36.1 million in Q4 2025, and -$35.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | -44.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.90 Mn |
| Dec 31, 2025 | -36.08 Mn |
| Sep 30, 2025 | -35.52 Mn |
| Jun 30, 2025 | -41.65 Mn |
| Mar 31, 2025 | -50.88 Mn |
| Dec 31, 2024 | 7.26 Mn |
| Sep 30, 2024 | -37.06 Mn |
| Jun 30, 2024 | -52.45 Mn |
| Mar 31, 2024 | -37.29 Mn |
| Dec 31, 2023 | -42.08 Mn |
| Sep 30, 2023 | -45.84 Mn |
| Jun 30, 2023 | -51.89 Mn |
| Mar 31, 2023 | -135.79 Mn |
| Dec 31, 2022 | -59.69 Mn |
| Sep 30, 2022 | -59.05 Mn |
| Jun 30, 2022 | -160.73 Mn |
| Mar 31, 2022 | -92.77 Mn |
| Dec 31, 2021 | -145.65 Mn |
| Sep 30, 2021 | -129.71 Mn |
| Jun 30, 2021 | -125.80 Mn |